Scarica l'app Stockscreener
18.93
4.50%
-0.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.79
Aprire:
$19.72
Volume 24 ore:
806.64K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.10B
Reddito:
$11.13M
Utile/perdita netta:
$-114.59M
Rapporto P/E:
-8.1842
EPS:
-2.313
Flusso di cassa netto:
$-113.96M
1 W Prestazione:
-7.13%
1M Prestazione:
-35.58%
6M Prestazione:
-21.80%
1 anno Prestazione:
+189.88%
Intervallo 1D:
$18.87
$19.92
Intervallo di 1 settimana:
$18.64
$20.49
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
18.91 | 1.15B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
475.31 | 122.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.55 | 70.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.01 | 54.72B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.78 | 38.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
266.74 | 36.23B | 4.29B | 577.22M | 641.34M | 4.2086 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity' - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
S&P 500, Dow, Nasdaq Futures Climb As Trump Says Iran Ceasefire Holds Despite Fresh Hormuz Tensions: IREN, CRWV, CAPR, TTD Stocks In Focus - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Investors in Capricor Therapeutics, Inc. Should Contact The Gros - GuruFocus
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Can Capricor Therapeutics’ (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility? - Sahm
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
ETFs Investing in Capricor Therapeutics, Inc. Stocks - TradingView
News | Capricor signs San Diego’s largest biotech lease of the year - CoStar
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
Cantor Fitzgerald reiterates Overweight on Capricor stock at $62 By Investing.com - Investing.com Canada
Capricor Therapeutics, Inc. Files Form 8-K: Company Details, Stock Information, and Key SEC Disclosures (July 2026) - Minichart
Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Michael T Maurer Net Worth (2026) - GuruFocus
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
Behavioral Patterns of CAPR and Institutional Flows - Stock Traders Daily
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Company Profile & Introduction - Moomoo
Price to earnings forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62 - Moomoo
Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision - Investing.com Canada
Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit NewsHas The Bull Case Changed? - Sahm
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus - Sahm
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business - Moomoo
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
CAPRCapricor Therapeutics Inc Volatility & Greeks - Finviz
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal - Sahm
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
(CAPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com India
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capricor Therapeutics Inc Azioni (CAPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.29%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):